Tetraphase to Present at Two Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that President and CEO Guy Macdonald will present a corporate update at the following investor conferences in New York, New York:

  • UBS Global Life Sciences Conference on September 19, 2011, at 12:00 p.m. Eastern time at The Grand Hyatt Hotel
  • JMP Securities Healthcare Conference on September 27, 2011, at 2:30 p.m. Eastern time at The St. Regis Hotel

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug-resistant and Gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com.



CONTACT:

Sam Brown Inc.
Mike Beyer, 773-463-4211
[email protected]

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.